The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease

• Published in: Acta neuropathologica communications 2018-11, Vol.6 (1), p.130-19, Article 130
• Main Authors: Twohig, Daniel, Rodriguez-Vieitez, Elena, Sando, Sigrid B, Berge, Guro, Lauridsen, Camilla, Møller, Ina, Grøntvedt, Gøril R, Bråthen, Geir, Patra, Kalicharan, Bu, Guojun, Benzinger, Tammie L S, Karch, Celeste M, Fagan, Anne, Morris, John C, Bateman, Randall J, Nordberg, Agneta, White, Linda R, Nielsen, Henrietta M
• Format: Article
• Language: English
• Subjects: alpha-synuclein; Alzheimer's disease; APOE epsilon 4; APOEε4; Biomarkers; Brain; Mild cognitive impairment; Mutation; Pathology; Studies
• ISSN: 2051-5960; 2051-5960
• DOI: 10.1186/s40478-018-0624-z

Accumulating evidence demonstrating higher cerebrospinal fluid (CSF) α-synuclein (αSyn) levels and αSyn pathology in the brains of Alzheimer's disease (AD) patients suggests that αSyn is involved in the pathophysiology of AD. To investigate whether αSyn could be related to specific aspects of the pathophysiology present in both sporadic and familial disease, we quantified CSF levels of αSyn and assessed links to various disease parameters in a longitudinally followed cohort (n = 136) including patients with sporadic mild cognitive impairment (MCI) and AD, and in a cross-sectional sample from the Dominantly Inherited Alzheimer's Network (n = 142) including participants carrying autosomal dominant AD (ADAD) gene mutations and their non-mutation carrying family members.Our results show that sporadic MCI patients that developed AD over a period of two years exhibited higher baseline αSyn levels (p = 0.03), which inversely correlated to their Mini-Mental State Examination scores, compared to cognitively normal controls (p = 0.02). In the same patients, there was a dose-dependent positive association between CSF αSyn and the APOEε4 allele. Further, CSF αSyn levels were higher in symptomatic ADAD mutation carriers versus non-mutation carriers (p = 0.03), and positively correlated to the estimated years from symptom onset (p = 0.05) across all mutation carriers. In asymptomatic (Clinical Dementia Rating